Pegvisomant
- Atc Codes:H01AX01
- CAS Codes:218620-50-9
- PHARMGKB ID:218620-50-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Somavert; Belgium: Somavert; Bulgaria: Somavert; Czech Republic: Somavert; Denmark: Somavert; Estonia: Somavert; Finland: Somavert; France: Somavert; Germany: Somavert; Greece: Somavert; Hungary: Somavert; Ireland: Somavert; Italy: Somavert; Latvia: Somavert; Lithuania: Somavert; Malta: Somavert; Netherlands: Somavert; Poland: Somavert; Portugal: Somavert; Romania: Somavert; Slovakia: Somavert; Slovenia: Somavert; Spain: Somavert; Sweden: Somavert; UK: Somavert.
North America
Canada: Somavert; USA: Somavert.
Latin America
Argentina: Somavert; Brazil: Somavert; Mexico: Somavert.
Asia
Japan: Somavert.
Drug combinations
Chemistry
Pegvisomant: Mw: approx. 50. 18-L-Aspartic acid-21-L-asparagine-120-L-lysine-167-L-asparagine-168-L-alanine-171-L-serine-172-L-arginine-174-serine-179-L-threonine growth hormone (human), reaction product with polyethylene glycol. CAS-218620-50-9 (1999).
Pharmacologic Category
Somatotropin Antagonists. Growth Hormone Receptor Antagonist. (ATC-Code: H01AX01).
Mechanism of action
Selectively binds to growth hormone receptors, blocking binding of endogenous growth hormone, leading to decreased serum concentrations of insulin-like growth factor-1 (IGF-1) and other growth hormone-responsive proteins. Pegvisomant is made up of a recombinant DNA protein covalently bound to polyethylene glycol polymers.
Therapeutic use
Treatment of acromegaly in patients resistant to or unable to tolerate other therapies.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to pegvisomant, polyethylene glycol, latex, or any other component of the formulation.
Warnings and precautions
Use may be associated with functional growth hormone deficiency. May increase liver function tests (transient but marked elevations in transaminase levels, usually without accompanying hyperbilirubinemia, reported)(use with caution in hepatic impairment). Lipohypertrophy may occur. Use with caution in diabetes mellitus (may affect glucose metabolism). Pegvisomant may expand growth hormone-secreting tumors causing serious complications. Vial stopper contains latex.